BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15789235)

  • 1. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
    Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schmid C; Schweiger C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):75-85. PubMed ID: 16091127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.
    Kremser A; Dressig J; Grabrucker C; Liepert A; Kroell T; Scholl N; Schmid C; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer H
    J Immunother; 2010; 33(2):185-99. PubMed ID: 20139775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Various 'dendritic cell antigens' are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Dreyssig J; Kremser A; Liepert A; Grabrucker C; Freudenreich M; Schmid C; Kroell T; Scholl N; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer HM
    Immunotherapy; 2011 Sep; 3(9):1113-24. PubMed ID: 21913833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro stimulation of specific antileukemia T-cell response by dendritic cells derived from CD14+ acute monocytic leukemia cells].
    Sheng LX; Xie XB; Qiu GQ; Gu WY; Wang ZL; Wu HQ
    Ai Zheng; 2005 Nov; 24(11):1338-44. PubMed ID: 16552959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions.
    Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H
    J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
    Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
    J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience.
    Bagheri K; Alimoghadam K; Pourfathollah AA; Hassan ZM; Hajati J; Moazzeni SM
    Pathol Oncol Res; 2009 Jun; 15(2):257-67. PubMed ID: 18807213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia.
    Narita M; Takahashi M; Liu A; Nikkuni K; Furukawa T; Toba K; Koyama S; Takai K; Sanada M; Aizawa Y
    Exp Hematol; 2001 Jun; 29(6):709-19. PubMed ID: 11378266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on Dendritic cells of leukemic origin (DC
    Ansprenger C; Amberger DC; Schmetzer HM
    Clin Immunol; 2020 Aug; 217():108467. PubMed ID: 32464186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia.
    Westers TM; Stam AG; Scheper RJ; Regelink JC; Nieuwint AW; Schuurhuis GJ; van de Loosdrecht AA; Ossenkoppele GJ
    Cancer Immunol Immunother; 2003 Jan; 52(1):17-27. PubMed ID: 12536236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses.
    Choudhury BA; Liang JC; Thomas EK; Flores-Romo L; Xie QS; Agusala K; Sutaria S; Sinha I; Champlin RE; Claxton DF
    Blood; 1999 Feb; 93(3):780-6. PubMed ID: 9920826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses.
    Brouwer RE; van der Hoorn M; Kluin-Nelemans HC; van Zelderen-Bhola S; Willemze R; Falkenburg JH
    Hum Immunol; 2000 Jun; 61(6):565-74. PubMed ID: 10825585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia.
    Zhong RK; Rassenti LZ; Kipps TJ; Chen J; Law P; Yu JF; Ball ED
    Biol Blood Marrow Transplant; 2002; 8(10):557-68. PubMed ID: 12434951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage.
    Re F; Arpinati M; Testoni N; Ricci P; Terragna C; Preda P; Ruggeri D; Senese B; Chirumbolo G; Martelli V; Urbini B; Baccarani M; Tura S; Rondelli D
    Exp Hematol; 2002 Feb; 30(2):126-34. PubMed ID: 11823047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy.
    Morse MA; Zhou LJ; Tedder TF; Lyerly HK; Smith C
    Ann Surg; 1997 Jul; 226(1):6-16. PubMed ID: 9242332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.